谷歌浏览器插件
订阅小程序
在清言上使用
VIPCreated with Sketch.

Safety and immunogenicity of anti-SARS CoV-2 conjugate vaccine SOBERANA 02 in a two-dose or three-dose heterologous scheme in adults: Phase IIb Clinical Trial

María Eugenia Toledo-Romani,Mayra García-Carmenate,Leslyhana Verdecia-Sánchez,Suzel Pérez-Rodríguez,Meybis Rodriguez-González,Carmen Valenzuela-Silva,Beatriz Paredes-Moreno,Belinda Sanchez-Ramirez,Raúl González-Mugica,Tays Hernández-Garcia,Ivette Orosa-Vázquez,Marianniz Díaz-Hernández,María Teresa Pérez-Guevara,Juliet Enriquez-Puertas,Enrique Noa-Romero,Ariel Palenzuela-Diaz,Gerardo Baro-Roman,Ivis Mendoza-Hernández,Yaima Muñoz,Yanet Gómez-Maceo,Bertha Leysi Santos-Vega,Sonsire Fernandez-Castillo,Yanet Climent-Ruiz,Laura Rodríguez-Noda,Darielys Santana-Mederos,Yanelda García-Vega,Guang Wu-Chen,Delaram Doroud,Alireza Biglari,Tammy Boggiano-Ayo,Yury Valdés-Balbín, Daniel García-Rivera,Dagmar García-Rivera,Vicente Vérez-Bencomo

medRxiv（2022）

引用 4|浏览15
暂无评分
关键词
vaccine,immunogenicity,anti-sars,two-dose,three-dose
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要